LOINC
Version 2.67

31201-7HIV 1+2 Ab [Presence] in Serum or Plasma by ImmunoassayActive

Part Description

LP16715-2   HIV 1+2
Two types of human immunodeficiency viruses (HIV) have been characterized: HIV-1 and HIV-2. HIV-1 was initially discovered in the early 1980s and thought to be the sole causative agent of HIV infections and ultimately AIDS. In 1986, HIV-2 was isolated and also found to cause AIDs. HIV-1 is more virulent and the predominant cause of the HIV infections worldwide. HIV-2 is poorly transmitted and is primarily concentrated in West Africa.

Presently (2012), HIV-1 strains are divided into four groups, including group M (major) with subtypes A through K, group O (outlier), group N (non-M or O), and group P. HIV-2 is divided into subtypes A through E. Occasionally, two viruses of different subtypes can "cross react" and blend their genetic material to create a new hybrid HIV virus. However, many of these new strains do not survive for long. Studies have also shown that the core proteins of HIV-1 and HIV-2 display frequent cross-reactivity whereas the envelope proteins are more type-specific. Source: Regenstrief LOINC

Fully-Specified Name

Component
HIV 1+2 Ab
Property
PrThr
Time
Pt
System
Ser/Plas
Scale
Ord
Method
IA

Additional Names

Short Name
HIV1+2 Ab SerPl Ql IA
Display Name
HIV 1+2 Ab IA Ql

Basic Attributes

Class
MICRO
Type
Laboratory
First Released
Version 2.07
Last Updated
Version 2.56
Change Reason
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016.
Order vs. Observation
Both
Common US Lab Results Rank
324
Common SI Lab Results Rank
324

Member of these Panels

LOINC Long Common Name
86636-8 Family planning report - FPAR 2.0 set
75622-1 HIV 1 and 2 tests - Meaningful Use set

Language Variants Get Info

zh-CNChinese (CHINA)
HIV 1 型+2 型 抗体:存在情况或阈值:时间点:血清/血浆:序数型:免疫测定法
nl-NLDutch (NETHERLANDS)
HIV 1+2 As:aanwezigheid:moment:serum of plasma:ordinaal:immunoassay
et-EEEstonian (ESTONIA)
HIV 1+2 antikehad:PrThr:Pt:S/P:Ord:IA
fr-BEFrench (BELGIUM)
VIH 1+2 Ac:PrThr:Temps ponctuel:Sérum/Plasma:Ordinal:IA
fr-CAFrench (CANADA)
VIH 1+2 , Ac:Présence-Seuil:Temps ponctuel:Sérum/Plasma:Ordinal:IA
fr-FRFrench (FRANCE)
VIH 1+2 Ac:Présence/Seuil:Ponctuel:Sérum/Plasma:Qualitatif:Immunoanalyse
fr-CHFrench (SWITZERLAND)
S--VIH 1+2, Ig; ; EIA
de-DEGerman (GERMANY)
HIV 1+2 Ak:AKnz:Pkt:Ser:Ord:EIA
de-CHGerman (SWITZERLAND)
S--HIV 1+2, Ig; ; EIA
el-GRGreek (GREECE)
HIV 1+2 Αντίσωμα:PrThr:Χρονική στιγμή:Ορός/Πλάσμα:Τακτική:IA
it-ITItalian (ITALY)
HIV 1+2 , Ab:PrThr:Pt:Siero/Plasma:Ord:IA
it-CHItalian (SWITZERLAND)
S--VIH 1+2, Ig; ; EIA
ko-KRKorean (KOREA, REPUBLIC OF)
사람 면역결핍 바이러스 1+2 항체:임의농도:검사시점:혈청:순위척도:효소면역측정법
pt-BRPortuguese (BRAZIL)
HIV 1+2 Ac:ACnc:Pt:Soro:Ord:Imunoensaio
ru-RURussian (RUSSIAN FEDERATION)
HIV 1+2 Ат:PrThr:ТчкВрм:Сыв/Плаз:Пор:IA
es-ARSpanish (ARGENTINA)
[anticuerpo anti - ] VIH 1+2 [Ac]:concentración arbitraria:punto en el tiempo:suero:ordinal:enzimoinmunoanálisis
es-ESSpanish (SPAIN)
VIH 1-2 Anticuerpos:PrThr:Punto temporal:Suero o Plasma:Ord:IA
es-CHSpanish (SWITZERLAND)
S--VIH 1+2, Ig; ; EIA
tr-TRTurkish (TURKEY)
HIV 1+2 Ab:MevcEşik:Zmlı:Ser/Plaz:Srl:İA

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=31201-7